Current Report Filing (8-k)
July 11 2017 - 5:18PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 11, 2017
Arena Pharmaceuticals, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
000-31161
|
|
23-2908305
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
6154 Nancy Ridge Drive,
San Diego, CA
|
|
|
|
92121
|
(Address of Principal Executive Offices)
|
|
|
|
(Zip Code)
|
Registrants Telephone Number, Including Area Code: (858)
453-7200
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instructions A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§ 240.12b-2
of
this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
In this report, Arena Pharmaceuticals, Arena, Company, we,
us and our refer to Arena Pharmaceuticals, Inc., and/or one or more of our wholly owned subsidiaries, unless the context otherwise provides. Arena Pharmaceuticals
®
and
Arena
®
are registered service marks of Arena Pharmaceuticals, Inc.
Item 2.02
|
Results of Operations and Financial Condition.
|
On July 11, 2017, we filed a preliminary prospectus
supplement with the Securities and Exchange Commission, or the SEC, in which we disclosed that we had cash and cash equivalents as of June 30, 2017 of $130.8 million, which includes approximately $0.2 million of cash held by Beacon
Discovery, Inc., a variable interest entity.
We are filing the following information with the SEC for the purpose of updating certain
aspects of the description of our business disclosed in our SEC reports.
Overview
We are a biopharmaceutical company focused on developing novel, small-molecule drugs with optimized receptor pharmacology designed to deliver broad clinical
utility across multiple therapeutic areas. Our proprietary pipeline includes potentially first- or best-in-class programs for which we own global commercial rights.
Our three most advanced clinical programs are:
|
|
|
Ralinepag
(formerly APD811) - an oral, next generation, selective IP receptor agonist targeting the prostacyclin pathway, for which we have reported positive topline results from our completed Phase 2
trial for pulmonary arterial hypertension, or PAH. Phase 3 trial preparations are ongoing.
|
|
|
|
Etrasimod
(formerly APD334) - an oral, next generation, selective sphingosine
1-phosphate,
or S1P, receptor modulator targeting the S1P receptor subtypes 1, 4 and 5,
which we are evaluating in multiple ongoing Phase 2 clinical trials for:
|
|
|
|
Ulcerative Colitis, or UC
|
|
|
|
Dermatological Extra-Intestinal Manifestations, or Derm EIMs, in Inflammatory Bowel Disease, or IBD
|
|
|
|
Pyoderma Gangrenosum, or PG, with and without
co-morbidities
including IBD
|
We also intend to initiate an additional trial in Primary Biliary Cholangitis, or PBC, in 2017.
|
|
|
APD371
- a highly selective, peripherally restricted, orally available, full agonist of the
cannabinoid-2
receptor, which we are evaluating in an ongoing Phase 2 clinical
trial for pain associated with Crohns disease
|
We intend to continue to explore additional indications for all of our
clinical-stage programs.
Additionally, we have collaborations with the following pharmaceutical companies:
|
|
|
Eisai Inc. and Eisai Co., Ltd. in their efforts with respect to BELVIQ
®
|
|
|
|
Axovant Sciences Ltd. in its efforts with respect to nelotanserin, an orally available inverse agonist of the serotonin 2A receptor, which is in (i) a Phase 2 clinical trial in Lewy body dementia patients who
experience frequent visual hallucinations, and (ii) a separate Phase 2 clinical trial to evaluate nelotanserin as a potential treatment for
rapid-eye-movement,
or
REM, behavior disorder in patients with dementia with Lewy bodies
|
|
|
|
Boehringer Ingelheim International GmbH targeting a G protein-coupled receptor that belongs to the group of orphan central nervous system receptors, which is in preclinical development
|
Recent Developments
Ralinepag
On July 10, 2017, we announced positive Phase 2 results for ralinepag. In this study, the primary efficacy analysis demonstrated a
statistically significant absolute change from baseline in pulmonary vascular resistance, or PVR, compared to placebo. Ralinepag also demonstrated numerical improvement in
6-minute
walk distance, or 6MWD.
The Phase 2 study was a randomized, double-blind, placebo-controlled, dose-ranging study in 61 adult patients with PAH, WHO/NYHA functional
class
II-IV.
Study medication was titrated over nine weeks, followed by a
13-week
treatment period. The primary efficacy analysis was absolute change from baseline in
PVR at week 22. Additional endpoints included change from baseline in
6-minute
walk test, proportion of subjects who exhibit clinical worsening and safety and tolerability. Patients who completed week 22 could
transition to an open-label ralinepag extension study.
Ralinepag improved median PVR by 163.9
dyn.s.cm-5
from baseline compared to a 0.7
dyn.s.cm-5
worsening from baseline in the placebo arm (P=0.02). Patients treated with ralinepag had a 29.8% improvement in PVR
compared to the placebo arm (P=0.03) and a 20.1% improvement in PVR compared to baseline. The study was not powered to show a difference in 6MWD from placebo and, while between group comparison directionally favored ralinepag, this was a not a
statistically-significant finding. Patients receiving ralinepag did demonstrate a 36m increase from baseline, a statistically significant within group increase.
Adverse events observed in the study were consistent with other prostacyclin treatments for the management of PAH, with headache, nausea,
diarrhea, jaw pain and flushing being the most commonly reported adverse events. Serious adverse events occurred in four (10%) of the patients taking ralinepag and in six (28.6%) of the patients taking placebo. There were no deaths among the
patients taking ralinepag and there were two deaths in the placebo group.
We plan to present full study results at future medical
congresses.
Etrasimod
We had
previously reported that the etrasimod Phase 2 study in ulcerative colitis would enroll up to 160 patients. We currently expect the final enrollment to be in the range of
120-160
patients.
APD371
We recently announced the design
of the ongoing Phase 2a investigation into the treatment of pain associated with Crohns disease. The study is a randomized, open-label, study to evaluate tolerability, pharmacokinetics, and efficacy in up to 20 subjects with Crohns
disease pain.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Arena Pharmaceuticals, Inc.
|
|
|
|
|
Date: July 11, 2017
|
|
|
|
By:
|
|
/s/ Amit D. Munshi
|
|
|
|
|
|
|
Amit D. Munshi
|
|
|
|
|
|
|
President and Chief Executive Officer
|
Arena Pharmaceuticals (NASDAQ:ARNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arena Pharmaceuticals (NASDAQ:ARNA)
Historical Stock Chart
From Apr 2023 to Apr 2024